Literature DB >> 23986348

IMPACT Study: Targeted Prostate Cancer Screening.

Christos Mikropoulos, Rosalind A Eeles.   

Abstract

Mesh:

Substances:

Year:  2013        PMID: 23986348      PMCID: PMC3755943          DOI: 10.1634/theoncologist.2013-0221

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
  7 in total

Review 1.  Perspectives on treatment of metastatic castration-resistant prostate cancer.

Authors:  Axel S Merseburger; Joaquim Bellmunt; Cheryl Jenkins; Chris Parker; John M Fitzpatrick
Journal:  Oncologist       Date:  2013-05-13

2.  Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

Authors:  David J Gallagher; Mia M Gaudet; Prodipto Pal; Tomas Kirchhoff; Lisa Balistreri; Kinjal Vora; Jasmine Bhatia; Zsofia Stadler; Samson W Fine; Victor Reuter; Michael Zelefsky; Michael J Morris; Howard I Scher; Robert J Klein; Larry Norton; James A Eastham; Peter T Scardino; Mark E Robson; Kenneth Offit
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

3.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

4.  Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.

Authors:  Anita V Mitra; Elizabeth K Bancroft; Yolanda Barbachano; Elizabeth C Page; C S Foster; C Jameson; G Mitchell; G J Lindeman; A Stapleton; G Suthers; D G Evans; D Cruger; I Blanco; C Mercer; J Kirk; L Maehle; S Hodgson; L Walker; L Izatt; F Douglas; K Tucker; H Dorkins; V Clowes; A Male; A Donaldson; C Brewer; R Doherty; B Bulman; P J Osther; M Salinas; D Eccles; K Axcrona; I Jobson; B Newcombe; C Cybulski; W S Rubinstein; S Buys; S Townshend; E Friedman; S Domchek; T Ramon Y Cajal; A Spigelman; S H Teo; N Nicolai; N Aaronson; A Ardern-Jones; C Bangma; D Dearnaley; J Eyfjord; A Falconer; H Grönberg; F Hamdy; O Johannsson; V Khoo; Z Kote-Jarai; H Lilja; J Lubinski; J Melia; C Moynihan; S Peock; G Rennert; F Schröder; P Sibley; M Suri; P Wilson; Y J Bignon; S Strom; M Tischkowitz; A Liljegren; D Ilencikova; A Abele; K Kyriacou; C van Asperen; L Kiemeney; D F Easton; Rosalind A Eeles
Journal:  BJU Int       Date:  2010-09-14       Impact factor: 5.588

Review 5.  Cancer risk in Lynch Syndrome.

Authors:  Emma Barrow; James Hill; D Gareth Evans
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

6.  Prostate cancer progression and survival in BRCA2 mutation carriers.

Authors:  Laufey Tryggvadóttir; Linda Vidarsdóttir; Tryggvi Thorgeirsson; Jon Gunnlaugur Jonasson; Elinborg Jona Olafsdóttir; Gudridur Helga Olafsdóttir; Thorunn Rafnar; Steinunn Thorlacius; Eirikur Jonsson; Jorunn Erla Eyfjord; Hrafn Tulinius
Journal:  J Natl Cancer Inst       Date:  2007-06-12       Impact factor: 13.506

7.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

Authors:  Elena Castro; Chee Goh; David Olmos; Ed Saunders; Daniel Leongamornlert; Malgorzata Tymrakiewicz; Nadiya Mahmud; Tokhir Dadaev; Koveela Govindasami; Michelle Guy; Emma Sawyer; Rosemary Wilkinson; Audrey Ardern-Jones; Steve Ellis; Debra Frost; Susan Peock; D Gareth Evans; Marc Tischkowitz; Trevor Cole; Rosemarie Davidson; Diana Eccles; Carole Brewer; Fiona Douglas; Mary E Porteous; Alan Donaldson; Huw Dorkins; Louise Izatt; Jackie Cook; Shirley Hodgson; M John Kennedy; Lucy E Side; Jacqueline Eason; Alex Murray; Antonis C Antoniou; Douglas F Easton; Zsofia Kote-Jarai; Rosalind Eeles
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.